David T. Rubin is the Joseph B. Kirsner Professor of Medicine, Professor of Pathology, Chief of the Section of Gastroenterology, Hepatology & Nutrition and Director of the Inflammatory Bowel Disease Center at the University of Chicago Medicine. He earned a medical degree with honors at The University of Chicago Pritzker School of Medicine where he also completed his residency in internal medicine and fellowships in gastroenterology and clinical medical ethics. He is associate faculty member at the MacLean Center for Clinical Medical Ethics, associate investigator at the University of Chicago Comprehensive Cancer Center and a member of the University of Chicago Committee on Clinical Pharmacology and Pharmacogenomics. He is the immediate past Chair of the National Scientific Advisory Committee of the Crohn’s & Colitis Foundation and current Chair of the International Organization for the Study of IBD.
Dr. Rubin’s research is focused on disease modification in IBD including clinical trial designs, novel measures of inflammation and prevention of adverse outcomes, and quality of life in IBD. He has twice received the ACG’s Governor’s Award of Excellence in Clinical Research (2003 and 2013), and in 2020, Dr. Rubin received the Sherman Prize for Excellence in Crohn’s and Colitis and in 2023, the UChicago Michael Reese Lectureship Award for outstanding faculty who have developed novel teaching and clinical research that advances healthcare, and separately, the distinguished UChicago Arthur H. Rubenstein Mentorship in Academic Medicine Award. He is Editor-in-Chief of the ACG On-Line Education Universe. Dr. Rubin is an editor of Curbside Consultation in IBD (3rd ed), senior editor of Sleisenger and Fordtran’s Gastrointestinal and Liver Disease (12th ed), and an author on >600 articles on management of IBD, including the 2019 and 2025 ACG Practice Guidelines for ulcerative colitis.
University of Chicago Pritzker School of Medicine
Chicago
Fellowship - Gastroenterology
2001
University of Chicago Pritzker School of Medicine
Chicago
Residency - Internal Medicine
1997
University of Chicago Pritzker School of Medicine
Chicago
MD
1994
University of Illinois
Urbana-Champaign
BS - Honors Biology
1990
Deployment of an Artificial Intelligence Histology Tool to Aid Qualitative Assessment of Histopathology Using the Nancy Histopathology Index in Ulcerative Colitis.
Deployment of an Artificial Intelligence Histology Tool to Aid Qualitative Assessment of Histopathology Using the Nancy Histopathology Index in Ulcerative Colitis. Inflamm Bowel Dis. 2025 Jun 13; 31(6):1630-1636.
PMID: 39284932
Health-Related Quality of Life Outcomes With Etrasimod Treatment in Patients With Ulcerative Colitis: A Post Hoc Analysis of Data From ELEVATE UC 52 and ELEVATE UC 12.
Health-Related Quality of Life Outcomes With Etrasimod Treatment in Patients With Ulcerative Colitis: A Post Hoc Analysis of Data From ELEVATE UC 52 and ELEVATE UC 12. Inflamm Bowel Dis. 2025 Jun 13; 31(6):1583-1594.
PMID: 39326009
Deucravacitinib in patients with inflammatory bowel disease: 12-week efficacy and safety results from 3 randomized phase 2 studies in Crohn's disease and ulcerative colitis.
Deucravacitinib in patients with inflammatory bowel disease: 12-week efficacy and safety results from 3 randomized phase 2 studies in Crohn's disease and ulcerative colitis. J Crohns Colitis. 2025 Jun 04; 19(6).
PMID: 40355364
An International Consensus on Appropriate Management of Corticosteroids in Clinical Trials in Inflammatory Bowel Disease.
An International Consensus on Appropriate Management of Corticosteroids in Clinical Trials in Inflammatory Bowel Disease. Gastroenterology. 2025 May 28.
PMID: 40446946
Incidence and Risk Factors for Development of Acne (JAKne) in Patients with Inflammatory Bowel Disease Treated With Upadacitinib.
Incidence and Risk Factors for Development of Acne (JAKne) in Patients with Inflammatory Bowel Disease Treated With Upadacitinib. Inflamm Bowel Dis. 2025 May 24.
PMID: 40411447
DIAGNOSIS AND MANAGEMENT OF UPPER GASTROINTESTINAL INVOLVEMENT IN ADULT PATIENTS WITH CROHN'S DISEASE: A SYSTEMATIC REVIEW.
DIAGNOSIS AND MANAGEMENT OF UPPER GASTROINTESTINAL INVOLVEMENT IN ADULT PATIENTS WITH CROHN'S DISEASE: A SYSTEMATIC REVIEW. Clin Gastroenterol Hepatol. 2025 May 14.
PMID: 40378982
Association of bile acid diarrhea with symptoms and disease activity in Crohn's disease: post-hoc clinical trial analysis of serum 7a-hydroxy-4cholestern-3-one, C4, in patients with active Crohn's disease.
Association of bile acid diarrhea with symptoms and disease activity in Crohn's disease: post-hoc clinical trial analysis of serum 7a-hydroxy-4cholestern-3-one, C4, in patients with active Crohn's disease. J Crohns Colitis. 2025 May 08; 19(5).
PMID: 40202488
Global evolution of inflammatory bowel disease across epidemiologic stages.
Global evolution of inflammatory bowel disease across epidemiologic stages. Nature. 2025 Jun; 642(8067):458-466.
PMID: 40307548
Shaping the future of inflammatory bowel disease: a global research agenda for better management and public health response.
Shaping the future of inflammatory bowel disease: a global research agenda for better management and public health response. Nat Rev Gastroenterol Hepatol. 2025 Jun; 22(6):438-452.
PMID: 40263433
The Effect of Etrasimod on Fecal Calprotectin and High-sensitivity C-reactive Protein: Results From the ELEVATE UC Clinical Program.
The Effect of Etrasimod on Fecal Calprotectin and High-sensitivity C-reactive Protein: Results From the ELEVATE UC Clinical Program. Inflamm Bowel Dis. 2025 Apr 10; 31(4):923-934.
PMID: 38899786